Download Champions' latest AACR 2025 Poster
Targeted immunotherapies in Multiple Myeloma: focus on flow cytometry markers and therapeutic implications
Multiple myeloma (MM), a common hematologic malignancy, presents ongoing challenges due to its clinical heterogeneity and development of resistance in relapsed or refractory cases. While immunotherapy has emerged as a powerful treatment modality, the identification of novel, targetable biomarkers is essential for advancing therapeutic options, particularly through immune-targeting strategies.
Champions Oncology developed a flexible flow cytometry-based screening platform using cryopreserved primary MM bone marrow samples, enabling deep phenotypic profiling and ex vivo drug sensitivity testing across clinically relevant MM models.
Champions Oncology developed a flexible flow cytometry-based screening platform using cryopreserved primary MM bone marrow samples, enabling deep phenotypic profiling and ex vivo drug sensitivity testing across clinically relevant MM models.
- Utilizing a custom-designed backbone panel with drop-in capability, researchers profiled MM subpopulations based on marker expression (CD38, CD56, CD117, CD138) across five patient samples and multiple MM cell lines, capturing the inherent heterogeneity of MM.
- Dimensionality reduction and marker expression analysis revealed distinct subpopulation profiles among treatment-naïve, refractory, and relapsed MM samples, facilitating the identification of unique signatures and therapeutic targets, such as CD319.
- Ex vivo drug screening with approved MM agents demonstrated model-specific drug sensitivities, validating the platform’s utility in functional characterization and translational evaluation of novel targets in MM.
Download the Poster